Find more photos like this on MedicsIndex.net - Family Safe Pages.com - Medical Social Network










HOME| Contact

Copyrights 1995-2007 Created and maintained by MBC











 Dr. Osama Abu Hlalah, M

Consultant Oncologist




King Hussein Cancer Centre ,Queen Rania street

                           P.O. Box 1269 Amman-Jordan 11941

            email: ohlalalh@khcc.jo, or osamahlalah@hotmail.com

  • Res.  +962-6-5345797

  • work + (962-6) 530-0460

  • Mobile +962-79-22261


Current Position






Consultant Oncologist: King Hussien Cancer Center, Amman-Jordan

Started July, 2006


Consultant Oncologist

Kentucky Cancer Clinic/ ARH Regional Medical Center

July 2005-July 2006

Summary of qualifications


n     American Board of Medical Oncology                            November 2005

n     American Board of Internal Medicine                               August, 2003

n     High Specialization Certificate in Internal Medicine (Master Degree): University of Jordan                                                          July, 2000

n     MB, BS (M.D): University of Jordan                                   June, 1995

n     ECFMG                                                                            August 1996

n     ATLS, ACLS, and PALS                                                     2003-2004



n     7/1/2003- 6/30/2005:

Fellow: Department of Hematology/Oncology

East Tennessee State University                                        Johnson City, TN

n     7/1/2000-6/30/2003:

Internal Medicine Resident

Mercy Catholic Medical Center 

(Hahnemann University)                                                    Philadelphia, PA

n     7/1/1996-6/30/2000    

Internal Medicine Resident

Jordan University Hospital                                                Amman, Jordan

n     7/1/1995-6/30/1996

Rotating Intern: AL-Bashir Hospital/Jordan University    Amman, Jordan

n     8/13/1989-6/12/1995:

Medical student: University of Jordan                                Amman, Jordan






Professional memberships


American College of Medicine

American Society of Clinical Oncology

Awards received


University of Jordan Award for Social Activities in 1993 for my role in establishing the Student Union of Jordan University

School of Pharmacy Award for Teaching in 1999 for my contribution in establishing and conducting Clinical Pharmacy Courses

Ranked the sixth highest score on the national level in the High School Certification Exam in 1989

Volunteer experience


I organized and conducted blood donation campaigns for Jordan University Hospital Blood Bank.

I participated in many outreach programs designed by my medical school to provide medical services for the rural and underserved population.

I served for 1 year on the Student Union as delegate for my Colleagues in the Medical School.

Research Experience


-I participated in a project that examined awareness of Colorectal Cancer practice guidelines among medical staff in Mercy Catholic Medical Center.

-East Tennessee State University: Cancer Chemoprevention Research that evaluates molecular growth parameters of prostate and colon cancer cells after treatment with Gamma Tocopherol

-Currently: I am the Sub-Investigator in the following trials conducted in Kentucky Cancer Clinic:

1- Protocol PO-01-003-050 that compares the efficacy of Gemcitabine maintenance or best supportive care following 4 cycles of standard combination chemotherapy in terms of survival from the time of randomization in advanced or metastatic NSCLC.



2-Protocol DO 410 : Multicenter randomized phase III study of Erlotinib (Tarceva) or placebo following concurrent Docetaxel, Carboplatin and thoracic radiation in patients with inoperable stage III NSCLC

3-Protocol DO 03-21-022: a randomized, open-label comparing treatment with either Pegylated Liposomal Doxorubicin or Capecitabine as first line chemotherapy for Metastatic Breast cancer in women 60 years and older

4-Protocol OS12950g : a phase II , multicenter , Randomized clinical trial to evaluate the efficacy and safety of Bevacizumab (Avastin) in combination with chemotherapy (Docetaxel or Pemetrexed) or Erlotinib (Tarceva) compared with chemotherapy alone for recurrent or refractory NSCLC